Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines

International Journal of Cancer

Volumn 116, Issue 1, 2005, Pages 122-129

  Bais, Aagje G ^a   Rebolj, Matejka ^a   Snijders, Peter J F ^b   De Schipper, Frits A ^c   Van Der Meulen, Dries A J ^b   Verheijen, René H M ^b   Voorhorst, Feja ^b   Van Ballegooijen, Marjolein ^a   Meijer, Chris J L M ^b   Helmerhorst, Theo J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Ziekenhuis Walcheren   (Netherlands)

Author keywords

Borderline or mild dyskaryosis; Guidelines; HPV; Triage

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DYSKARYOSIS; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TIME; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 20444461643     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20958     Document Type: Article

References (38)

1. Bulkmans NWJ, Rozendaal L, Snijdeis PJF, Voorhorst FJ, Boeke AJP, Zandwijken GRJ, van Kemenade FJ, Verheijen RHM, van Groningen K, Boon ME, Keuning HJF, van Ballegooijȩn M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
2. van Ballegooijen M, Rebolj M, Meerding WJ, van den Akker-van Marle ME, Berkers LM, Habbema JDF. De praktijk van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland in 2001: rapport in het kader van de landelijke evaluatie van het bevolkingsonderzoek naar baarmoederhalskanker (LEBA): Deel 3. 2003.
3. Teale GR, Moffit DD, Mann CH, Luelsy DM. Management guidelines for women with normal colposcopy after low grade cervical abnormalities: population study. Br Med J 2000;320:1693-6.
4. Östor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynaecol Pathol 1993;12:186-92.
5. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998;91:973-6.
6. Van Ballegooijen M, Koopmanschap MA, Habbema JDF. The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands. Eur J Cancer 1995;31:1672-76.
7. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CLJM, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
8. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
9. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Br Med J 2002;325:572-8.
10. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
11. Remmink AJ, Walboomers JMM, Helmerhorst ThJM, Voorhorts FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
12. Nobbenhuis MAE, Walboomers JMM, Helmerhorst ThJM, Rozendaal L, Remmink AJ, Risse EK, Van der Linden JC, Voorhorst FJ, Kenemans P, Meijer CLJM. Relation of human papillomavirus status to cervical lesions and consequences for cervical-screening: a prospective study. Lancet 1999;354:20-5.
13. Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000;53:606-11.
14. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
15. Manos MM, Kinney WK, Hurley LB, Sherman M, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia. Using human papillomavirus testing for equivocal Papanicolaou results. JAMA 1999;281:1605-9.
16. Meijer CJ, Helmerhorst TJ, Rozendaal L, van der Linden JC, Voorhorst FJ, Walboomers JM. HPV typing and testing in gynaecological pathology: has the time come? Histopathology 1998;33:83-6.
17. Solomon D, Schiffman M, Tarone R;ALTS group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
18. Hughes SA, Sun D, Gibson C, Bellerose B, Rushing L, Chen H, Harlow BL, Genest DR, Sheets EE, Crum CP. Managing atypical squamous cells of undetermined significance (ASCUS): human papillomavirus testing, ASCUS subtyping, or follow-up cytology. Am J Obstet Gynecol 2002;186:396-403.
19. Zielinski GD, Snijders PJF, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP, de Schipper FA, Meijer CLJM. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398-404.
20. Ho L, Terry G, Londesborough P, Cuzick J, Lorenzato F, Singer A. Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears. J Med Virol 2003;69:118-21.
21. Schiffman M, Wheeler CM, Castle PE;ALTS group. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J Infect Dis 2002;186:1169-72.
22. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker E. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3:1-196.
23. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, etl al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6.
24. Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996;89:257-60.
25. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
26. Jacobs MV, Snijders PJF, van den Brule AJC, Helmerhorst ThJM, Meijer CLJM, Walboomers JMM. A general primer GP5+/6+ mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-95.
27. Jacobs MV, Zielinski GD, Meijer CLJM, Pol RP, Voorhorst FJ, de Schipper FA, Runsink AP, Snijders PJF, Walboomers JMM. A simplified and reliable HPV testing of archival Papanicolaou-stained archival smears: application to cervical smears from cancer patients starting with cytologically normal smears. Br J Cancer 2000;82:1421-6.
28. Nobbenhuis MAE, Helmerhorst ThJM, van den Brule AJC, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RHM, Meijer CLJM. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358: 1782-3.
29. ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data form a randomized trial. J Natl Cancer Inst 2000;92:397-402.
30. Sherman M, Schiffmann M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002; 94:102-7.
31. Guido R, Schiffmann M, Solomon D, Burke L(ALTS-group). Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003;188:1401-5.
32. Cox JT, Schiffmann M, Solomon D(ALTS-group). Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188:1406-12.
33. Snijders PJF, van den Brule AJC, Meijer CLJM. The clinical relevance of HPV-testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
34. Van den Akker-van Marle ME, van Ballegooijen M, Rozendaal L, Meijer CLJM, Habbema JDF. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 2003;89:1830-3.
35. van Oortmarssen GJ, Habbema JD. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol 1995;24:300-7.
36. Dillner J. Cervical cancer screening in Sweden. Eur J Cancer 2000; 36:2255-9.
37. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
38. Helmerhorst TJM, Meijer CLJM. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 2002;12:235-6.